Software-driven pet health company Anivive Lifesciences announced on Monday that it has secured USD20m in funding from investment firm Leonid Capital Partners.

This investment is intended to help Anivive bolster its research programs, expand its manufacturing capabilities and drive commercialisation of its canine vaccine for Valley fever, the first-ever antifungal vaccine. Anivive's direct-to-veterinarian sales platform Engage launched in early 2024 and has already processed over 9,000 orders.

The investment from Leonid Capital Partners follows Anivive's recent USD33m contract with the National Institutes of Health to support the development of a human vaccine against the fungus Coccidioides, which causes Valley fever. Across its pipeline, Anivive now has USD80m in preorders and commitments from industry partners.